Media headlines about AstraZeneca (NYSE:AZN) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AstraZeneca earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.1281642195618 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of AstraZeneca (NYSE AZN) traded up $0.13 during trading hours on Thursday, hitting $35.40. 2,760,000 shares of the company’s stock were exchanged, compared to its average volume of 3,080,000. The firm has a market cap of $88,360.00, a price-to-earnings ratio of 25.29, a P/E/G ratio of 3.44 and a beta of 0.76. AstraZeneca has a 52 week low of $26.51 and a 52 week high of $35.92. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.
AstraZeneca (NYSE:AZN) last issued its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.55. The company had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $1.32 EPS. sell-side analysts expect that AstraZeneca will post 1.88 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect AstraZeneca (AZN) Share Price” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/11/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-astrazeneca-azn-share-price.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.